Company Overview and News
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
Procter & Gamble Co (NYSE:PG) stock took a hit following its earnings announcement. Although the company beat on both revenue and net income, earnings guidance disappointed Wall Street. Most of its peers in the consumer defensive sector also saw stock price drops on slower-than-expected growth.
Shares of Procter & Gamble (PG - Free Report) are down roughly 13% over the last year as the consumer packaged goods giant faces tougher competition from rivals and upstarts. With that said, earnings season could give Procter & Gamble a much needed shot in the arm, if it impresses investors.
Kimberly-Clark Corporation (KMB - Free Report) is slated to release first-quarter 2018 results on Apr 23. This consumer goods company has reported an average earnings surprise of nearly 2% over the trailing four quarters. Let’s see how things are placed ahead of the upcoming results.
There’s nothing more thrilling than being able to tell the tale of an incredible stock trade that dished out massive, short-term gains. Though most of these proverbial “whale hunts” don’t pan out as initially hoped, enough of them do to keep investors ever-searching for them.
The Zacks Cosmetics industry has been glowing on consumer’ increased spending on beauty products, which has helped it rally 49% in a year, comfortably beating the S&P 500’s gain of 15.5%. Well, the industry (ranked among the top 48% out of more than 250 Zacks industries) has been riding on solid performances by renowned players like The Estee Lauder Companies Inc. (EL - Free Report) and Nu Skin Enterprises, Inc.
Volatility is back and that's good. Finally, we get some action. Still, the future returns from stocks as an asset isn't that great and it's understandable that some people go for bonds or other "safe" assets. However, with my time horizon, I can't afford to try to time the market and luckily, the market isn't crazy about the kind of stocks that I like. That being said, it's really hard to find good value when the S&P trades at close to a forward P/E 16.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Petrobras (PBR) and Walgreens Boots Alliance (WBA). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Bed Bath & Beyond Inc. (BBBY - Free Report) is slated to release fourth-quarter fiscal 2017 results on Apr 11. The question lingering in investors’ minds is whether or not this home furnishings retailer will be able to deliver a positive earnings surprise in the quarter to be reported. The company posted a positive earnings surprise of 22.2% in the last reported quarter. However, it lagged the Zacks Consensus Estimate by an average of 1.
Wall Street is off to a disastrous start in the second quarter. Major bourses tumbled into correction for the second time this year and closed below key technical levels. Elevated trade tensions between the United States and China along with weakness in large-cap tech stocks are cited to be the reasons for the free fall.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET